# Resistant Hypertension Secondary Cause Testing

In apparent resistant hypertension, first confirm sustained out-of-office blood pressure elevation and treatment exposure, then pursue targeted testing for primary aldosteronism, obstructive sleep apnea, kidney disease, renovascular disease, medication effects, and selected endocrine disorders.

**Clinical question:** Which secondary-cause tests should be ordered after confirming apparent resistant hypertension?

Updated: 2026-09-15T17:42:34.206601+00:00

## What matters in practice
- Define resistant hypertension only after excluding white-coat effect with ambulatory or home blood pressure monitoring and addressing adherence; resistant hypertension is uncontrolled blood pressure on at least 3 agents including a diuretic, or controlled blood pressure requiring at least 4 agents.[5][13][17]
- Screen all patients with resistant hypertension for primary aldosteronism using plasma aldosterone-to-renin testing; normal potassium does not exclude the diagnosis.[1][18]
- Obstructive sleep apnea is a high-yield target: in one systematically evaluated resistant-hypertension cohort, apnea-hypopnea index greater than 15 events/hour was present in 64%.[6]
- Use history, examination, kidney function, potassium, renin-aldosterone pattern, and sleep evaluation to direct renal artery imaging, adrenal imaging, metanephrine testing, thyroid testing, and polysomnography rather than ordering all tests indiscriminately.[16][17][23]

## Confirm true resistant hypertension before secondary-cause testing

Apparent resistance becomes actionable only after out-of-office confirmation and regimen review.

Classify the patient as having apparent treatment-resistant hypertension when blood pressure remains uncontrolled despite at least 3 concurrently prescribed antihypertensive agents at optimized doses, including a diuretic, or when control requires at least 4 agents.[5][17][22] Before assigning true resistance, review the medication list for a long-acting thiazide or thiazide-like diuretic and establish whether each prescribed agent is being taken; multidrug nonadherence is specifically recognized as a setting in which device-based therapy should not substitute for correcting the underlying problem.[8]

Obtain ambulatory blood pressure monitoring (ABPM) when available to confirm uncontrolled hypertension, identify white-coat hypertension, assess nocturnal hypertension or nondipping, and determine whether pressure is controlled across the full 24-hour dosing interval.[13] Home blood pressure monitoring is the practical alternative for longitudinal follow-up and detection of white-coat or masked hypertension.[13] Do not initiate an extensive secondary-hypertension evaluation solely from persistently elevated office values when ABPM or reliable home readings do not confirm sustained elevation.

At the same encounter, identify reversible exogenous contributors by reconciling prescription drugs, over-the-counter agents, supplements, alcohol and other substances. Drug causes were included in systematic evaluations of resistant hypertension alongside sleep apnea, primary aldosteronism, renal disease, renovascular disease, pheochromocytoma, Cushing syndrome, coarctation, and thyroid disorders.[6] The finding of a likely drug contributor should prompt withdrawal or substitution when feasible, followed by reassessment with home blood pressure monitoring before escalating to invasive testing.
- Order ABPM when office and home readings disagree, resistant hypertension is suspected, nocturnal hypertension is clinically relevant, or treatment-related symptomatic hypotension is possible.[13]
- Use serial home blood pressure monitoring for long-term treated-hypertension follow-up; repeat ABPM every 2 to 3 months until a normal 24-hour profile is obtained when hypertension remains uncontrolled, and consider annual ABPM once controlled.[13]
- Treat resistant hypertension as a high-risk phenotype: it is associated with greater target-organ damage and cardiovascular complications than controlled hypertension.[6]

*Tests that establish whether apparent resistant hypertension warrants a secondary-cause workup.[5][13][17]*

| Finding | Test or review | Interpretation and next action |
| --- | --- | --- |
| Persistent office hypertension on 3 or more agents | ABPM; use home blood pressure monitoring if ABPM is unavailable | Confirm sustained uncontrolled blood pressure before labeling true resistant hypertension; assess nighttime control and possible white-coat effect.[13] |
| Blood pressure controlled only with 4 or more agents | Medication and adherence review plus out-of-office blood pressure assessment | Meets resistant-hypertension definition despite controlled clinic blood pressure; proceed with a structured secondary-cause screen when true resistance is confirmed.[17][22] |
| No diuretic or nonoptimized multidrug regimen | Reconcile doses, timing, tolerability, and diuretic exposure | Optimize the foundational regimen before interpreting treatment failure as biologic resistance.[5][8] |
| Suspected nonadherence or multidrug intolerance | Direct medication history and regimen simplification where possible | Correct exposure barriers before considering invasive escalation such as renal denervation.[8] |

## Use baseline phenotype to select the secondary-cause branch

A focused initial panel separates renal, aldosterone-mediated, sleep-related, and catecholamine or thyroid patterns.

Obtain serum potassium, renal function testing, and a targeted renal and endocrine evaluation in confirmed resistant hypertension. In published resistant-hypertension evaluations, the secondary workup included serum potassium, renin, aldosterone, plasma metanephrines, thyroid function tests, 24-hour urinary potassium, renal artery ultrasonography or computed tomography angiography, adrenal CT or MRI, and polysomnography, selected according to history, examination, and baseline laboratory findings.[17]

Do not use hypokalemia as a gatekeeper for primary aldosteronism testing. Primary aldosteronism commonly presents as hypertension without classical hypokalemia, and multiple hypertension and endocrine societies recommend aldosterone-to-renin screening in resistant hypertension.[1] Conversely, potassium status, sodium loading, pregnancy, antihypertensive drugs, obstructive sleep apnea, and renal insufficiency can alter the aldosterone-renin ratio (ARR), including producing false-negative results.[18]

Use the clinical phenotype to sequence testing. Kidney dysfunction or urinalysis abnormalities should move renal parenchymal disease forward; a low-renin aldosterone-mediated pattern should move primary aldosteronism forward; snoring, witnessed apnea, daytime somnolence, or nocturnal blood pressure abnormalities should move sleep testing forward; and paroxysmal hyperadrenergic spells, a suggestive family history, or an adrenal mass should move metanephrine testing forward.[6][16][17]
- Order plasma-free metanephrines or 24-hour urinary fractionated metanephrines when pheochromocytoma is clinically suspected; plasma testing may be more sensitive but less specific, whereas urine testing is suggested by some experts when pretest probability is lower.[16]
- Add thyroid function tests when clinical findings or unexplained resistant hypertension raise concern for thyroid disease; thyroid disorders were identified during systematic resistant-hypertension evaluations.[6][17]
- Consider 24-hour urinary potassium when potassium wasting may help characterize a mineralocorticoid or renal tubular phenotype.[17]

*Phenotype-directed testing for common and consequential secondary causes in resistant hypertension.[6][16][17][23]*

| Clinical or laboratory clue | First targeted test | Result that changes the next step |
| --- | --- | --- |
| Resistant hypertension with or without hypokalemia | Plasma aldosterone-to-renin ratio | A positive screen requires primary-aldosteronism confirmation and subtype evaluation; do not dismiss the condition because potassium is normal.[1][18] |
| Snoring, witnessed apnea, daytime sleepiness, obesity, nondipping or nocturnal hypertension | Sleep study, typically polysomnography | Sleep-disordered breathing supports obstructive sleep apnea as a treatable contributor; apnea-hypopnea index greater than 15 events/hour defined OSA in a resistant-hypertension cohort.[6][17] |
| Reduced kidney function, albuminuria, urinary abnormalities, or longstanding renal disease | Renal function assessment and kidney-directed evaluation | Prioritize renal parenchymal disease and volume-related contributors; CKD frequently coexists with resistant hypertension.[5][14][17] |
| Abrupt or severe hypertension with renovascular features | Renal artery ultrasound or computed tomography angiography | Anatomic renal artery disease redirects evaluation toward renovascular hypertension and an individualized revascularization assessment.[17] |
| Hyperadrenergic spells, adrenal lesion, hereditary predisposition, or previous pheochromocytoma | Plasma-free metanephrines or 24-hour urinary fractionated metanephrines | Biochemical evidence should prompt adrenal or extra-adrenal localization and endocrine-directed management.[16] |
| Early-onset hypertension, especially before age 40 years, or blood pressure above 160/100 mm Hg | Broaden secondary-hypertension screening based on phenotype | Early onset or marked hypertension increases the indication to investigate obstructive sleep apnea, renovascular disease, primary aldosteronism, renal disease, and other causes.[23] |

## Screen primary aldosteronism with aldosterone-to-renin testing

Resistant hypertension is a guideline-supported indication for ARR screening.

Obtain plasma aldosterone and renin together and interpret the ARR as a screening test, not as a standalone subtype diagnosis. Resistant hypertension is a consistent indication because national and international societies recommend screening this group with a plasma aldosterone-to-plasma renin activity ratio.[1] A suppressed renin result with inappropriately elevated aldosterone should lead to confirmatory testing and endocrine referral rather than empiric attribution to essential hypertension.

Correct and document potassium status before interpreting a negative screen. Negative ARR results can occur with altered potassium status, sodium loading, pregnancy, antihypertensive drugs, obstructive sleep apnea, and renal insufficiency; renal vascular injury may permit renin escape and obscure the expected suppression pattern.[18] If the pretest probability remains high after a negative or equivocal test—particularly with resistant hypertension and hypokalemia—repeat biochemical evaluation under conditions that address modifiable interferents.

After biochemical confirmation, use adrenal imaging and adrenal venous sampling when determining whether unilateral adrenalectomy is appropriate. A published diagnostic pathway for primary aldosteronism used confirmatory testing followed by bilateral adrenal venous sampling to establish lateralization.[10] This distinction matters because, in appropriately selected surgically correctable primary aldosteronism, adrenalectomy compared with empiric medical therapy was associated with lower all-cause mortality, longer freedom from atrial fibrillation, and less chronic kidney disease.[1]
- Normal serum potassium does not exclude primary aldosteronism and should not prevent ARR screening in resistant hypertension.[1]
- Interpret a negative ARR cautiously in CKD, obstructive sleep apnea, pregnancy, sodium loading, or when antihypertensive therapy and potassium status may alter renin or aldosterone values.[18]
- Use adrenal CT or MRI after biochemical evidence of primary aldosteronism as part of subtype assessment; use adrenal venous sampling when lateralization will determine candidacy for unilateral adrenalectomy.[10][17]
- If surgery is not pursued or bilateral disease is present, mineralocorticoid receptor antagonism is the disease-directed pharmacologic strategy; spironolactone and eplerenone are identified as relevant agents in resistant hypertension.[8][9]

*Primary aldosteronism testing sequence in resistant hypertension.[1][10][18]*

| Step | Action | Pitfall or decision consequence |
| --- | --- | --- |
| Screen | Measure plasma aldosterone and renin; calculate ARR | Resistant hypertension warrants screening even without hypokalemia.[1] |
| Validate | Review potassium status, sodium exposure, pregnancy, renal function, obstructive sleep apnea, and antihypertensive drugs | Each can alter ARR interpretation and contribute to a false-negative result.[18] |
| Confirm | Perform confirmatory testing after a positive biochemical screen | Confirmation distinguishes persistent autonomous aldosterone excess from a screening abnormality.[10] |
| Subtype | Use adrenal imaging and bilateral adrenal venous sampling when surgery is being considered | Lateralization identifies patients who may benefit from unilateral adrenalectomy rather than empiric medical treatment.[1][10] |

## Test sleep apnea, renal disease, and renovascular disease according to phenotype

These causes often coexist; one positive test should not terminate evaluation when the blood pressure pattern remains discordant.

Evaluate obstructive sleep apnea early in resistant hypertension. In a cohort in which patients underwent systematic testing regardless of symptoms, obstructive sleep apnea defined by an apnea-hypopnea index greater than 15 events/hour was found in 64.0%, compared with 5.6% for primary aldosteronism, 2.4% for renal artery stenosis, and 1.6% for renal parenchymal disease.[6] Order polysomnography or another appropriate sleep study when the sleep history, examination, nocturnal blood pressure pattern, or high resistant-hypertension pretest probability supports the diagnosis.[15][17]

Assess for renal parenchymal disease with renal function testing and kidney-directed clinical evaluation, then use urine findings and the broader renal phenotype to guide next testing. Renal parenchymal disease and chronic kidney disease are repeatedly identified secondary or contributing conditions in resistant hypertension.[5][14][17] In CKD, volume retention and altered renin-aldosterone physiology can coexist, so a renal explanation does not automatically exclude primary aldosteronism.[18]

Reserve renal artery imaging for patients with a clinical renovascular phenotype rather than using it as universal screening. Renal artery ultrasonography and CT angiography are established modalities used in resistant-hypertension secondary-cause assessments.[17] If imaging identifies renal artery disease, interpret it in context: atherosclerosis is the most common cause of renovascular hypertension, while fibromuscular and other arterial abnormalities remain relevant etiologies in selected patients.[16]
- Use ABPM when sleep apnea is suspected and the question includes nocturnal hypertension, nondipping, or whether blood pressure is controlled throughout the dosing interval.[13]
- Do not stop after diagnosing obstructive sleep apnea if there is persistent hypokalemia, a low-renin phenotype, or otherwise compelling evidence for primary aldosteronism; both conditions can affect ARR interpretation and may coexist.[18]
- Consider coarctation in selected patients with upper-extremity hypertension and an anatomic or examination pattern suggesting aortic obstruction; renal hypoperfusion with renin-angiotensin-aldosterone activation may contribute to hypertension.[16]

*Practical differentiation of sleep, renal, and renovascular contributors.[6][13][16][17]*

| Etiologic branch | Most useful next test | Interpretation |
| --- | --- | --- |
| Obstructive sleep apnea | Polysomnography or appropriate sleep study; ABPM when nocturnal pattern is relevant | An apnea-hypopnea index greater than 15 events/hour was the threshold used to define OSA in a resistant-hypertension cohort; ABPM identifies nocturnal hypertension and nondipping.[6][13] |
| Renal parenchymal disease | Renal function assessment with kidney-directed evaluation | CKD and renal parenchymal disease can sustain resistant hypertension and complicate renin-aldosterone interpretation.[14][17][18] |
| Renovascular hypertension | Renal artery ultrasonography or CT angiography | Positive anatomic findings support a renovascular branch; atherosclerosis is the most common renovascular cause.[16][17] |
| Aortic coarctation | Focused vascular examination followed by anatomic imaging when suspected | Upper-extremity hypertension with evidence of obstruction should prompt evaluation because renal hypoperfusion can activate RAAS.[16] |

## Reserve uncommon endocrine testing and procedures for a compatible phenotype

Testing intensity should rise with pretest probability and the prospect of cause-directed intervention.

Order metanephrine testing when resistant hypertension is accompanied by hyperadrenergic spells, an adrenal mass with imaging features concerning for pheochromocytoma, family history, a predisposing genetic syndrome, or prior pheochromocytoma. Plasma-free metanephrines may be slightly more sensitive but less specific than 24-hour urinary fractionated metanephrines; urine testing is an option when pretest probability is lower, while plasma testing is favored by some experts when it is higher.[16] A positive biochemical result should trigger localization and endocrine management rather than empiric antihypertensive escalation alone.

Evaluate Cushing syndrome, thyroid disease, and other rare causes only when the history, examination, or baseline testing points toward the disorder. Cushing syndrome and thyroid disorders were among conditions sought in systematic resistant-hypertension evaluations.[6] For example, an adrenal lesion with evidence of cortisol nonsuppression requires assessment for cortisol co-secretion because primary aldosteronism and autonomous cortisol production can coexist.[7]

Refer patients with confirmed or strongly suspected endocrine hypertension, equivocal ARR with persistent high pretest probability, suspected renovascular hypertension requiring an intervention decision, or refractory hypertension despite at least 5 drug classes including a long-acting thiazide or thiazide-like diuretic and a mineralocorticoid receptor antagonist.[8] Renal denervation is not a diagnostic substitute and should be avoided with unfavorable renal artery anatomy, heavily calcified or tortuous aorta, aortic aneurysm, prior dissection, increased bleeding risk, advanced CKD, pregnancy, or prior renal intervention.[8]
- Use adrenal imaging to localize after biochemical endocrine evidence, not as a replacement for biochemical testing or lateralization in primary aldosteronism.[10][17]
- Consider spironolactone as the preferred fourth-line pharmacologic approach for true resistant hypertension; eplerenone, amiloride, doxazosin, clonidine, and beta-blockers are alternatives when spironolactone is not tolerated or contraindicated.[9][19]
- If spironolactone is not tolerated because of clinically significant hyperkalemia or another contraindication, obtain hypertension-specialist input for alternative therapy selection.[9]

*Escalation decisions after targeted secondary-cause testing.[8][9][16]*

| Situation | Action | Key constraint |
| --- | --- | --- |
| High pretest probability of pheochromocytoma | Measure plasma-free metanephrines | Plasma testing may be more sensitive but less specific than urinary testing.[16] |
| Lower pretest probability of pheochromocytoma | Consider 24-hour urinary fractionated metanephrines | Urine testing may be preferred by some experts when suspicion is lower.[16] |
| True resistant hypertension after confirmation and evaluation | Add spironolactone when tolerated; use alternatives if contraindicated or not tolerated | Clinically significant hyperkalemia is a reason to avoid or discontinue mineralocorticoid receptor antagonism and seek specialist advice.[9][19] |
| Refractory hypertension despite 5 or more drug classes including thiazide-like diuretic and mineralocorticoid receptor antagonist | Refer for advanced hypertension management; consider procedural options only after selection review | Renal denervation requires suitable renal arterial anatomy and is contraindicated in several vascular, bleeding, pregnancy, and renal settings.[8] |

## Common questions

### Should every patient with resistant hypertension undergo renal artery imaging?

No. Renal artery ultrasound or CT angiography is best directed by a renovascular clinical phenotype; these modalities are part of targeted secondary-cause assessment rather than universal screening.[17]

### Does normal potassium exclude primary aldosteronism?

No. Primary aldosteronism commonly presents without classical hypokalemia, and resistant hypertension remains an indication for aldosterone-to-renin screening.[1]

## References
1. Screening Rates for Primary Aldosteronism in Resistant Hypertension | Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.14359
2. Endocrine causes of hypertension: literature review and practical approach | Hypertension Research — www.nature.com — https://www.nature.com/articles/s41440-023-01461-1
3. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations | JACC — www.jacc.org — https://www.jacc.org/doi/abs/10.1016/j.jacc.2022.07.005
4. Assessing the Accuracy of an Online Chat-Based Artificial Intelligence Model in Providing Recommendations on Hypertension Management in Accordance With the 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension Guidelin... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.21183
5. Resistant Hypertension: Diagnosis, Evaluation, and Treatment — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hypertensionaha.108.189141
6. Obstructive Sleep Apnea | Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.111.179788?doi=10.1161%2FHYPERTENSIONAHA.111.179788
7. A Case of Primary Aldosteronism Associated with Renal Artery Stenosis and Preclinical Cushing's Syndrome | Hypertension Research — www.nature.com — https://www.nature.com/articles/hr2008213
8. 2022 Renal denervation therapy for the treatment of hypertension — www.nature.com — https://www.nature.com/articles/s41440-022-01133-6
9. Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement | Journal of Human Hypertension — www.nature.com — https://www.nature.com/articles/s41371-024-00983-6
10. Successful treatment of resistant hypertension and severe complications in a 63-year-old man with primary aldosteronism without adrenalectomy: A case report — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)09719-6
11. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109722055930
12. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines | European Heart Journal | Oxford Academic — academic.oup.com — https://academic.oup.com/eurheartj/article/43/35/3302/6661233
13. 2021 European Society of Hypertension practice... : Journal of Hypertension — journals.lww.com — https://journals.lww.com/jhypertension/fulltext/2021/07000/2021_european_society_of_hypertension_practice.5.aspx
14. The double challenge of resistant hypertension and chronic kidney disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0140673615004183
15. Secondary hypertension: Obstructive sleep apnea - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1933171115000303
16. Renovascular Disease - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/renovascular-disease
17. Associated factors and hemodynamic characteristics of resistant hypertension in the elderly — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jch.14640
18. Case series: Primary aldosteronism diagnosed despite normal ... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2023/05190/case_series__primary_aldosteronism_diagnosed.33.aspx
19. Revisiting resistant hypertension: a comprehensive review — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/imj.16189
20. Abstract - 2025 - European Journal of Heart Failure — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3736
21. Drug Therapy for Resistant Hypertension: Simplifying the Approach — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2010.00387.x
22. Primary hyperaldosteronism presenting as... : Medicine: Case Reports and Study Protocols — journals.lww.com — https://journals.lww.com/md-cases/fulltext/2021/03000/primary_hyperaldosteronism_presenting_as_resistant.10.aspx
23. Clinical practice guideline for the management of hypertension in ... — journals.lww.com — https://journals.lww.com/cmj/fulltext/2024/12200/clinical_practice_guideline_for_the_management_of.2.aspx
24. HYPERTENSIVE EMERGENCY DUE TO RESISTANT ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(25)02309-8/fulltext

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.